Erratum: Gomisin G inhibits the growth of triple-negative breast cancer cells by suppressing AKT phosphorylation and decreasing cyclin D1 (Biomol.Ther., (2018) 26, (322-327), 10.4062/biomolther.2017.235);Gomisin G inhibits the growth of triple-negative breast cancer cells by suppressing AKT phosphorylation and decreasing cyclin D1

Biomolecules and Therapeutics

Volumn 26, Issue 3, 2018, Pages 322-327

  Maharjan, Sony ^a   Park, Byoung Kwon ^a   Lee, Su In ^a   Lim, Yoonho ^b   Lee, Keunwook ^a   Kwon, Hyung Joo ^a  

^a Hallym University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

AKT; Cell cycle; Cell proliferation; Cyclin D1; Gomisin G; Triple negative breast cancer

Indexed keywords

CYCLIN D1; GOMISIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; RETINOBLASTOMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; MDA-MB-231 CELL LINE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; TRIPLE NEGATIVE BREAST CANCER;

EID: 85046724299     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2018.520     Document Type: Erratum

References (32)

1. Alao, J. P. (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 24.
2. Altomare, D. A. and Testa, J. R. (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24, 7455-7464.
3. Anders, C. K. and Carey, L. A. (2009) Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin. Breast Cancer 9 Suppl 2, S73-S81.
4. Arcaro, A. and Guerreiro, A. S. (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr. Genomics 8, 271-306.
5. Bartkova, J., Lukas, J., Muller, H., Lutzhoft, D., Strauss, M. and Bartek, J. (1994) Cyclin D1 protein expression and function in human breast cancer. Int. J. Cancer 57, 353-361.
6. Caputi, M., Groeger, A. M., Esposito, V., Dean, C., De Luca, A., Pa-cilio, C., Muller, M. R., Giordano, G. G., Baldi, F., Wolner, E. and Giordano, A. (1999) Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am. J. Respir. Cell. Mol. Biol. 20, 746-750.
7. Casimiro, M. C., Crosariol, M., Loro, E., Li, Z. and Pestell, R. G. (2012) Cyclins and cell cycle control in cancer and disease. Genes Cancer 3, 649-657.
8. Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A. and McCubrey, J. A. (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17, 590-603.
9. Chavez, K. J., Garimella, S. V. and Lipkowitz, S. (2010) Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35-48.
10. Chen, D. F., Zhang, S. X., Xie, L., Xie, J. X., Chen, K., Kashiwada, Y., Zhou, B. N., Wang, P., Cosentino, L. M. and Lee, K. H. (1997) Anti-AIDS agents--XXVI. Structure-activity correlations of gomisin-G-related anti-HIV lignans from Kadsura interior and of related synthetic analogues. Bioorg. Med. Chem. 5, 1715-1723.
11. Choi, Y. W., Takamatsu, S., Khan, S. I., Srinivas, P. V., Ferreira, D., Zhao, J. and Khan, I. A. (2006) Schisandrene, a dibenzocyclooctadiene lignan from Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans. J. Nat. Prod. 69, 356-359.
12. Collignon, J., Lousberg, L., Schroeder, H. and Jerusalem, G. (2016) Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med. Press) 8, 93-107.
13. Criscitiello, C., Azim, H. A., Jr., Schouten, P. C., Linn, S. C. and Sotiri-ou, C. (2012) Understanding the biology of triple-negative breast cancer. Ann. Oncol. 23 Suppl 6, vi13-vi18.
14. Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P. and Narod, S. A. (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429-4434.
15. Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H. et al. (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 3, 524-548.
16. Foulkes, W. D., Smith, I. E. and Reis-Filho, J. S. (2010) Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948.
17. Hutchinson, L. (2010) Breast cancer: challenges, controversies, breakthroughs. Nat. Rev. Clin. Oncol. 7, 669-670.
18. Jang, M. K., Yun, Y. R., Kim, J. H., Park, M. H. and Jung, M. H. (2017) Gomisin N inhibits adipogenesis and prevents high-fat diet-induced obesity. Sci. Rep. 7, 40345.
19. Kang, J. I., Hong, J. Y., Choi, J. S. and Lee, S. K. (2016) Columbiana-din inhibits cell proliferation by inducing apoptosis and necroptosis in HCT116 colon cancer cells. Biomol. Ther. (Seoul) 24, 320-327.
20. Kim, E. J., Kang, J. I., Tung, N. H., Kim, Y. H., Hyun, J. W., Koh, Y. S., Chang, W. Y., Yoo, E. S. and Kang, H. K. (2016) The effect of (1S,2S,3E,7E,11E)-3,7,11,15-Cembratetraen-17,2-Olide (LS-1) from lobophyyum sp. on the apoptosis induction of SNU-C5 human colorectal cancer cells. Biomol. Ther. (Seoul) 24, 623-629.
21. Min, H. Y., Park, E. J., Hong, J. Y., Kang, Y. J., Kim, S. J., Chung, H. J., Woo, E. R., Hung, T. M., Youn, U. J., Kim, Y. S., Kang, S. S., Bae, K. and Lee, S. K. (2008) Antiproliferative effects of dibenzocyclooctadiene lignans isolated from Schisandra chinensis in human cancer cells. Bioorg. Med. Chem. Lett. 18, 523-526.
22. Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A. and Sutherland, R. L. (2011) Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer 11, 558-572.
23. Oh, S. Y., Kim, Y. H., Bae, D. S., Um, B. H., Pan, C. H., Kim, C. Y., Lee, H. J. and Lee, J. K. (2010) Anti-inflammatory effects of gomisin N, gomisin J, and schisandrin C isolated from the fruit of Schisandra chinensis. Biosci. Biotechnol. Biochem. 74, 285-291.
24. Opletal, L., Sovova, H. and Bartlova, M. (2004) Dibenzo[a,c]cycloocta-diene lignans of the genus Schisandra: importance, isolation and determination. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 812, 357-371.
25. Otto, T. and Sicinski, P. (2017) Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer. 17, 93-115.
26. Pareja, F., Geyer, F. C., Marchio, C., Burke, K. A., Weigelt, B. and Reis- Filho, J. S. (2016) Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants. NPJ Breast Cancer 2, 16036.
27. Park, H. J., Lee, S. J., Song, Y., Jang, S. H., Ko, Y. G., Kang, S. N., Chung, B. Y., Kim, H. D., Kim, G. S. and Cho, J. H. (2014) Schisandra chinensis prevents alcohol-induced fatty liver disease in rats. J. Med. Food 17, 103-110.
28. Qie, S. and Diehl, J. A. (2016) Cyclin D1, cancer progression, and opportunities in cancer treatment. J. Mol. Med. 94, 1313-1326.
29. Robinson, T. J., Liu, J. C., Vizeacoumar, F., Sun, T., Maclean, N., Egan, S. E., Schimmer, A. D., Datti, A. and Zacksenhaus, E. (2013) RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE 8, e78641.
30. Ryu, E. Y., Park, S. Y., Kim, S. G., Park, D. J., Kang, J. S., Kim, Y. H., Seetharaman, R., Choi, Y. W. and Lee, S. J. (2011) Anti-inflammatory effect of heme oxygenase-1 toward Porphyromonas gingivalis lipopolysaccharide in macrophages exposed to gomisins A, G, and J. J. Med. Food 14, 1519-1526.
31. VanArsdale, T., Boshoff, C., Arndt, K. T. and Abraham, R. T. (2015) Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin. Cancer Res. 21, 2905-2910.
32. Xiaoyang, L., Chenming, N., Chengqing, L. and Tao, L. (2015) Drug-drug interation prediction between ketoconazole and anti-liver cancer drug Gomisin G. Afr. Health Sci. 15, 590-593.